VITROS IMMUNODIAGNOSTIC PRODUCTS ANTI-HCV REAGENT PACK AND CALIBRATOR

Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus

FDA Premarket Approval P010021

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the vitros immunodiagnostic products anti-hcv reagent pack and vitros immunodiagnostic products anti-hcv calibrator. These devices are indicated for: the vitros immunodiagnostic products anti-hcv reagent pack is indicated for the in vitro qualitative detection of immunoglobulin g antibody to hepatitis c virus (anti-hcv) in human serum and plasma (heparin, edta and sodium citrate) using the vitros eci immunodiagnostic system. Three recombinant hepatitis c virus encoded antigens are used. Assay results, in conjunction with other laboratory results and clinical information, may be used to provide presumptive evidence of infection with hepatitis c virus (state or associated disease not determined) in persons with signs or symptoms of hepatitis and in persons at risk for hepatitis c infection. The vitros immunodiagnostic products anti-hcv calibrator is indicated for use in the calibration of the vitros eci immunodiagnostic system for the in vitro qualitative detection of immunoglobulin g antibody to hepatitis c virus (anti-hcv) in human serum and plasma (heparin, edta and sodium citrate) using vitros anti-hcv reagent packs. The vitros anti-hcv calibrator has been validated for use only on the vitros eci immunodiagnostic system with the vitros immunodiagnostic products anti-hcv reagent pack.

DeviceVITROS IMMUNODIAGNOSTIC PRODUCTS ANTI-HCV REAGENT PACK AND CALIBRATOR
Classification NameAssay, Enzyme Linked Immunosorbent, Hepatitis C Virus
Generic NameAssay, Enzyme Linked Immunosorbent, Hepatitis C Virus
ApplicantOrtho-Clinical Diagnostics, Inc.
Date Received2001-04-02
Decision Date2001-08-30
Notice Date2001-12-05
PMAP010021
SupplementS
Product CodeMZO
Docket Number01M-0536
Advisory CommitteeMicrobiology
Expedited ReviewNo
Combination Product No
Applicant Address Ortho-Clinical Diagnostics, Inc. 100 Indigo Creek Dr. rochester, NY 14626-5101
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P010021Original Filing
S033 2020-07-20 30-day Notice
S032 2019-05-21 30-day Notice
S031 2018-10-16 Normal 180 Day Track No User Fee
S030 2018-02-21 Normal 180 Day Track No User Fee
S029 2018-01-09 Normal 180 Day Track No User Fee
S028 2016-10-21 30-day Notice
S027 2015-08-10 30-day Notice
S026 2015-06-25 30-day Notice
S025 2014-11-17 135 Review Track For 30-day Notice
S024 2013-02-08 30-day Notice
S023 2012-10-17 30-day Notice
S022 2012-01-30 30-day Notice
S021 2011-10-05 Real-time Process
S020 2011-06-14 135 Review Track For 30-day Notice
S019 2011-03-24 135 Review Track For 30-day Notice
S018 2010-04-26 30-day Notice
S017 2009-12-01 Normal 180 Day Track No User Fee
S016 2009-03-30 Normal 180 Day Track
S015 2009-03-06 30-day Notice
S014 2008-11-13 Normal 180 Day Track No User Fee
S013 2008-03-20 Real-time Process
S012 2008-01-23 30-day Notice
S011 2007-06-05 30-day Notice
S010 2007-03-28 30-day Notice
S009
S008 2005-11-16 30-day Notice
S007 2005-09-16 Normal 180 Day Track
S006 2005-06-27 135 Review Track For 30-day Notice
S005 2005-02-02 Special (immediate Track)
S004 2004-10-26 30-day Notice
S003 2004-07-16 30-day Notice
S002 2004-07-07 30-day Notice
S001 2003-04-11 30-day Notice

NIH GUDID Devices

Device IDPMASupp
10758750002801 P010021 024
10758750001101 P010021 024
10758750001095 P010021 024

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.